Is your business fit to scale?

Our new report shows that workplace culture is a key determining factor in fitness to scale. Ed Lascelles says ‘Ignore it at your peril’. For the full study and recommendations

Click here

20+ years

Experience of investing in technology

c. £450m

Venture capital currently invested

40+

Technology investments within our portfolio

UCLTF

In collaboration with UCLB Albion manages the UCL technology fund

AlbionVC typically invests £2m-5m into B2B software companies and marketplaces at Series A.

AlbionVC also manages the UCL Technology Fund, which makes seed stage investments in IP created by UCL. Notable exits to date include Grapeshot (Oracle), Opta (Perform), Active Hotels/ Booking.com (Priceline), Bloomsbury (Facebook) and Orchard Therapeutics (NASDAQ).

Tech Investment Team drinks and nibbles at NOBU
Article

AlbionVC typically invests £2m-5m into B2B software companies and marketplaces at Series A.

AlbionVC also manages the UCL Technology Fund, which makes seed stage investments in IP created by UCL. Notable exits to date include Grapeshot (Oracle), Opta (Perform), Active Hotels/ Booking.com (Priceline), Bloomsbury (Facebook) and Orchard Therapeutics (NASDAQ).

Rob Hendersons – on PAUG
Insight

AlbionVC typically invests £2m-5m into B2B software companies and marketplaces at Series A.

AlbionVC also manages the UCL Technology Fund, which makes seed stage investments in IP created by UCL. Notable exits to date include Grapeshot (Oracle), Opta (Perform), Active Hotels/ Booking.com (Priceline), Bloomsbury (Facebook) and Orchard Therapeutics (NASDAQ).

Forward Healthcare joins Albion portfolio
News

AlbionVC typically invests £2m-5m into B2B software companies and marketplaces at Series A.

AlbionVC also manages the UCL Technology Fund, which makes seed stage investments in IP created by UCL. Notable exits to date include Grapeshot (Oracle), Opta (Perform), Active Hotels/ Booking.com (Priceline), Bloomsbury (Facebook) and Orchard Therapeutics (NASDAQ).